Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.

Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P  =  .02) and overall survival (OS; aHR 4.55; P  =  .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P  =  .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P  =  .02 and aHR 6.89; P < .01, respectively).

Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.

Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.

Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6

Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.

Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P  =  .02) and overall survival (OS; aHR 4.55; P  =  .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P  =  .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P  =  .02 and aHR 6.89; P < .01, respectively).

Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.

Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.

Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6

Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.

Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P  =  .02) and overall survival (OS; aHR 4.55; P  =  .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P  =  .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P  =  .02 and aHR 6.89; P < .01, respectively).

Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.

Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.

Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6

Key clinical point: A low baseline albumin level is significantly associated with hyperprogressive disease (HPD) development and worse survival outcomes after programmed cell death-1 (PD-1) blockade in patients with advanced gastric cancer (AGC).

Major finding: The optimal albumin cut-off value for predicting HPD was <3.25 mg/dL, with an area under the receiver operating curve of 0.7708 (P  =  .0022). Patients with albumin levels of <3.25 mg/dL had worse progression-free (hazard ratio [HR] 1.928; 95% CI 1.289-2.885) and overall (HR 1.833; 95% CI 1.211-2.774) survival.

Study details: This retrospective study included 169 patients with AGC who received PD-1 blockade therapy (nivolumab or pembrolizumab; n = 112) or irinotecan monotherapy (n = 57).

Disclosures: This study was funded by the National Research Foundation of Korea by the Korean government, among others. The authors declared no conflicts of interest.

Source: Kim CG et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387-399 (Jul 13). Doi: 10.1016/j.ejca.2022.05.042

Key clinical point: A low baseline albumin level is significantly associated with hyperprogressive disease (HPD) development and worse survival outcomes after programmed cell death-1 (PD-1) blockade in patients with advanced gastric cancer (AGC).

Major finding: The optimal albumin cut-off value for predicting HPD was <3.25 mg/dL, with an area under the receiver operating curve of 0.7708 (P  =  .0022). Patients with albumin levels of <3.25 mg/dL had worse progression-free (hazard ratio [HR] 1.928; 95% CI 1.289-2.885) and overall (HR 1.833; 95% CI 1.211-2.774) survival.

Study details: This retrospective study included 169 patients with AGC who received PD-1 blockade therapy (nivolumab or pembrolizumab; n = 112) or irinotecan monotherapy (n = 57).

Disclosures: This study was funded by the National Research Foundation of Korea by the Korean government, among others. The authors declared no conflicts of interest.

Source: Kim CG et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387-399 (Jul 13). Doi: 10.1016/j.ejca.2022.05.042

Key clinical point: A low baseline albumin level is significantly associated with hyperprogressive disease (HPD) development and worse survival outcomes after programmed cell death-1 (PD-1) blockade in patients with advanced gastric cancer (AGC).

Major finding: The optimal albumin cut-off value for predicting HPD was <3.25 mg/dL, with an area under the receiver operating curve of 0.7708 (P  =  .0022). Patients with albumin levels of <3.25 mg/dL had worse progression-free (hazard ratio [HR] 1.928; 95% CI 1.289-2.885) and overall (HR 1.833; 95% CI 1.211-2.774) survival.

Study details: This retrospective study included 169 patients with AGC who received PD-1 blockade therapy (nivolumab or pembrolizumab; n = 112) or irinotecan monotherapy (n = 57).

Disclosures: This study was funded by the National Research Foundation of Korea by the Korean government, among others. The authors declared no conflicts of interest.

Source: Kim CG et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387-399 (Jul 13). Doi: 10.1016/j.ejca.2022.05.042

Key clinical point: Despite lower complete resection rates and a higher risk for recurrence, endoscopic resection (ER) offers similar long-term survival outcomes and serious adverse event (AE) rates and shorter hospital stays compared with surgery in early gastric cancer (EGC).

Major finding: The ER vs surgery group had a lower complete resection rate (risk difference [RD] −0.1; P < .00001), shorter length of hospital stay (P < .00001), higher rate of recurrence (RD 0.07; P < .00001), and comparable 5-year overall survival (RD −0.01; P  =  .38), cancer-specific survival (RD 0.01; P < .17), and serious AE rate (RD −0.03; P  =  .13).

Study details: This was a meta-analysis of 29 observational cohort studies (prospective: n = 2; retrospective: n = 27) involving 20,559 patients with EGC who underwent ER (n = 7709) or surgery (n = 12,850).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Bestetti AM et al. endoscopic resection versus surgery in the treatment of early gastric cancer: A systematic review and meta-analysis. Front Oncol. 2022;12:939244 (Jul 12). Doi: 10.3389/fonc.2022.939244

Key clinical point: Despite lower complete resection rates and a higher risk for recurrence, endoscopic resection (ER) offers similar long-term survival outcomes and serious adverse event (AE) rates and shorter hospital stays compared with surgery in early gastric cancer (EGC).

Major finding: The ER vs surgery group had a lower complete resection rate (risk difference [RD] −0.1; P < .00001), shorter length of hospital stay (P < .00001), higher rate of recurrence (RD 0.07; P < .00001), and comparable 5-year overall survival (RD −0.01; P  =  .38), cancer-specific survival (RD 0.01; P < .17), and serious AE rate (RD −0.03; P  =  .13).

Study details: This was a meta-analysis of 29 observational cohort studies (prospective: n = 2; retrospective: n = 27) involving 20,559 patients with EGC who underwent ER (n = 7709) or surgery (n = 12,850).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Bestetti AM et al. endoscopic resection versus surgery in the treatment of early gastric cancer: A systematic review and meta-analysis. Front Oncol. 2022;12:939244 (Jul 12). Doi: 10.3389/fonc.2022.939244

Key clinical point: Despite lower complete resection rates and a higher risk for recurrence, endoscopic resection (ER) offers similar long-term survival outcomes and serious adverse event (AE) rates and shorter hospital stays compared with surgery in early gastric cancer (EGC).

Major finding: The ER vs surgery group had a lower complete resection rate (risk difference [RD] −0.1; P < .00001), shorter length of hospital stay (P < .00001), higher rate of recurrence (RD 0.07; P < .00001), and comparable 5-year overall survival (RD −0.01; P  =  .38), cancer-specific survival (RD 0.01; P < .17), and serious AE rate (RD −0.03; P  =  .13).

Study details: This was a meta-analysis of 29 observational cohort studies (prospective: n = 2; retrospective: n = 27) involving 20,559 patients with EGC who underwent ER (n = 7709) or surgery (n = 12,850).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Bestetti AM et al. endoscopic resection versus surgery in the treatment of early gastric cancer: A systematic review and meta-analysis. Front Oncol. 2022;12:939244 (Jul 12). Doi: 10.3389/fonc.2022.939244

Key clinical point: Preoperative plasma levels of the appetite-regulating gut hormone ghrelin may predict postoperative weight loss in patients who have undergone subtotal gastrectomy (STG) for gastric cancer.

Major finding: After adjusting for confounders, the area under the curve preoperative ghrelin level showed a significant negative correlation (ρ –0.8; P  =  .024) with the change in weight loss in the 4 months after STG.

Study details: Findings are from a prospective study including 13 patients aged 20-75 years with gastric cancer who underwent STG and 14 controls with no history of gastrointestinal surgery.

Disclosures: This study was supported by The Korean Society of Neurogastroenterology and Motility. The authors declared no conflicts of interest.

Source: Jung HK et al. Association between gut regulatory hormones and post-operative weight loss following gastrectomy in patients with gastric cancer. J Neurogastroenterol Motil. 2022;28(3):409-417 (Jul 30). Doi: 10.5056/jnm21145

Key clinical point: Preoperative plasma levels of the appetite-regulating gut hormone ghrelin may predict postoperative weight loss in patients who have undergone subtotal gastrectomy (STG) for gastric cancer.

Major finding: After adjusting for confounders, the area under the curve preoperative ghrelin level showed a significant negative correlation (ρ –0.8; P  =  .024) with the change in weight loss in the 4 months after STG.

Study details: Findings are from a prospective study including 13 patients aged 20-75 years with gastric cancer who underwent STG and 14 controls with no history of gastrointestinal surgery.

Disclosures: This study was supported by The Korean Society of Neurogastroenterology and Motility. The authors declared no conflicts of interest.

Source: Jung HK et al. Association between gut regulatory hormones and post-operative weight loss following gastrectomy in patients with gastric cancer. J Neurogastroenterol Motil. 2022;28(3):409-417 (Jul 30). Doi: 10.5056/jnm21145

Key clinical point: Preoperative plasma levels of the appetite-regulating gut hormone ghrelin may predict postoperative weight loss in patients who have undergone subtotal gastrectomy (STG) for gastric cancer.

Major finding: After adjusting for confounders, the area under the curve preoperative ghrelin level showed a significant negative correlation (ρ –0.8; P  =  .024) with the change in weight loss in the 4 months after STG.

Study details: Findings are from a prospective study including 13 patients aged 20-75 years with gastric cancer who underwent STG and 14 controls with no history of gastrointestinal surgery.

Disclosures: This study was supported by The Korean Society of Neurogastroenterology and Motility. The authors declared no conflicts of interest.

Source: Jung HK et al. Association between gut regulatory hormones and post-operative weight loss following gastrectomy in patients with gastric cancer. J Neurogastroenterol Motil. 2022;28(3):409-417 (Jul 30). Doi: 10.5056/jnm21145

Key clinical point: Computed tomography-determined low skeletal muscle mass (SMM) predicts worse overall survival (OS) in patients with gastric cancer and associated cachexia but not in those without cachexia.

Major finding: Patients with a low vs normal SMM had a significantly worse OS (P  =  .007). A low SMM significantly predicted worse OS in patients with cachexia (P  =  .009) but not in those without cachexia (P  =  .31).

Study details: This retrospective study included 255 adult patients with gastric cancer, of which 117 had low SMM including 49 patients with cachexia.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Wan Q et al. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia. Cancer Med. 2022 (Jul 18). Doi: 10.1002/cam4.5040

Key clinical point: Computed tomography-determined low skeletal muscle mass (SMM) predicts worse overall survival (OS) in patients with gastric cancer and associated cachexia but not in those without cachexia.

Major finding: Patients with a low vs normal SMM had a significantly worse OS (P  =  .007). A low SMM significantly predicted worse OS in patients with cachexia (P  =  .009) but not in those without cachexia (P  =  .31).

Study details: This retrospective study included 255 adult patients with gastric cancer, of which 117 had low SMM including 49 patients with cachexia.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Wan Q et al. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia. Cancer Med. 2022 (Jul 18). Doi: 10.1002/cam4.5040

Key clinical point: Computed tomography-determined low skeletal muscle mass (SMM) predicts worse overall survival (OS) in patients with gastric cancer and associated cachexia but not in those without cachexia.

Major finding: Patients with a low vs normal SMM had a significantly worse OS (P  =  .007). A low SMM significantly predicted worse OS in patients with cachexia (P  =  .009) but not in those without cachexia (P  =  .31).

Study details: This retrospective study included 255 adult patients with gastric cancer, of which 117 had low SMM including 49 patients with cachexia.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Wan Q et al. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia. Cancer Med. 2022 (Jul 18). Doi: 10.1002/cam4.5040

Key clinical point: In patients with early gastric cancer or gastric adenoma, the curative resection rate with endoscopic submucosal dissection (ESD) for lesions sized ≥5 cm is approximately two-thirds of that for lesions <5 cm; however, delayed perforation is more common in the former.

Major finding: In patients with ≥5 and <5 cm lesions, the curative resection rates were 65.6% and 91.5%, respectively, with the rate of delayed perforation being significantly higher in the former (1.6% and 0.1%, respectively; P  =  .019).

Study details: This multicenter retrospective study included 3410 ESD-treated  gastric lesions in patients aged ≥20 years with early gastric cancer or gastric adenoma and categorized them according to lesion size: <5 cm (n = 3282) and ≥5 cm (n = 128).

Disclosures: This study received no external funding. The authors declared no conflicts of interest.

Source: Chiba H et al. The feasibility and safety of endoscopic submucosal dissection of gastric lesions larger than 5 cm. Gastric Cancer. 2022 (Jul 25). Doi: 10.1007/s10120-022-01323-8

Key clinical point: In patients with early gastric cancer or gastric adenoma, the curative resection rate with endoscopic submucosal dissection (ESD) for lesions sized ≥5 cm is approximately two-thirds of that for lesions <5 cm; however, delayed perforation is more common in the former.

Major finding: In patients with ≥5 and <5 cm lesions, the curative resection rates were 65.6% and 91.5%, respectively, with the rate of delayed perforation being significantly higher in the former (1.6% and 0.1%, respectively; P  =  .019).

Study details: This multicenter retrospective study included 3410 ESD-treated  gastric lesions in patients aged ≥20 years with early gastric cancer or gastric adenoma and categorized them according to lesion size: <5 cm (n = 3282) and ≥5 cm (n = 128).

Disclosures: This study received no external funding. The authors declared no conflicts of interest.

Source: Chiba H et al. The feasibility and safety of endoscopic submucosal dissection of gastric lesions larger than 5 cm. Gastric Cancer. 2022 (Jul 25). Doi: 10.1007/s10120-022-01323-8

Key clinical point: In patients with early gastric cancer or gastric adenoma, the curative resection rate with endoscopic submucosal dissection (ESD) for lesions sized ≥5 cm is approximately two-thirds of that for lesions <5 cm; however, delayed perforation is more common in the former.

Major finding: In patients with ≥5 and <5 cm lesions, the curative resection rates were 65.6% and 91.5%, respectively, with the rate of delayed perforation being significantly higher in the former (1.6% and 0.1%, respectively; P  =  .019).

Study details: This multicenter retrospective study included 3410 ESD-treated  gastric lesions in patients aged ≥20 years with early gastric cancer or gastric adenoma and categorized them according to lesion size: <5 cm (n = 3282) and ≥5 cm (n = 128).

Disclosures: This study received no external funding. The authors declared no conflicts of interest.

Source: Chiba H et al. The feasibility and safety of endoscopic submucosal dissection of gastric lesions larger than 5 cm. Gastric Cancer. 2022 (Jul 25). Doi: 10.1007/s10120-022-01323-8

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).

Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ² 4.468; P  =  .035) and higher 2-year RFS rate (62.9% and 37.8%).

Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).

Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.

Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9

Key clinical point: Endoscopic resection (ER) achieves favorable long-term survival outcomes in patients with early gastric cancer (EGC) in the real-world setting.

Major finding: The overall 5-year overall survival (OS) rate was 89.0% (95% CI 88.3%-89.6%). The lower limit of the 95% CI for the 5-year OS rate exceeded the threshold 5-year OS rate in all categories of pathological curability, including curative resection for expanded indications.

Study details: The data come from a multicenter prospective cohort study, J-WEB/EGC, that included 9054 patients with 10,021 EGC lesions who underwent ER.

Disclosures: This study was supported by the Japanese Ministry of Health, Labour, and Welfare, and Daiwa Securities Health Foundation. The authors declared no conflicts of interest.

Source: Suzuki H et al. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2022 (Aug 7). Doi: 10.1016/j.cgh.2022.07.029

Key clinical point: Endoscopic resection (ER) achieves favorable long-term survival outcomes in patients with early gastric cancer (EGC) in the real-world setting.

Major finding: The overall 5-year overall survival (OS) rate was 89.0% (95% CI 88.3%-89.6%). The lower limit of the 95% CI for the 5-year OS rate exceeded the threshold 5-year OS rate in all categories of pathological curability, including curative resection for expanded indications.

Study details: The data come from a multicenter prospective cohort study, J-WEB/EGC, that included 9054 patients with 10,021 EGC lesions who underwent ER.

Disclosures: This study was supported by the Japanese Ministry of Health, Labour, and Welfare, and Daiwa Securities Health Foundation. The authors declared no conflicts of interest.

Source: Suzuki H et al. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2022 (Aug 7). Doi: 10.1016/j.cgh.2022.07.029

Key clinical point: Endoscopic resection (ER) achieves favorable long-term survival outcomes in patients with early gastric cancer (EGC) in the real-world setting.

Major finding: The overall 5-year overall survival (OS) rate was 89.0% (95% CI 88.3%-89.6%). The lower limit of the 95% CI for the 5-year OS rate exceeded the threshold 5-year OS rate in all categories of pathological curability, including curative resection for expanded indications.

Study details: The data come from a multicenter prospective cohort study, J-WEB/EGC, that included 9054 patients with 10,021 EGC lesions who underwent ER.

Disclosures: This study was supported by the Japanese Ministry of Health, Labour, and Welfare, and Daiwa Securities Health Foundation. The authors declared no conflicts of interest.

Source: Suzuki H et al. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol. 2022 (Aug 7). Doi: 10.1016/j.cgh.2022.07.029

Key clinical point: Laparoscopic distal gastrectomy was surgically and oncologically noninferior to open distal gastrectomy in patients with locally advanced gastric cancer throughout the 5-year follow-up period.

Major finding: Patients who underwent laparoscopic vs open distal gastrectomy had a significantly lower late complication rate (6.5% vs 11.0%; P  =  .01), but similar 5-year overall survival (88.9% vs 88.7%; P  =  .30) and relapse-free survival (79.5% vs 81.1%; P  =  .658) rates.

Study details: This study reports the 5-year follow-up results of the KLASS-02 trial that included 974 patients with locally advanced gastric cancer who underwent R0 resection by laparoscopic (n = 492) or open (n = 482) distal gastrectomy.

Disclosures: This study was sponsored by the National R&D Program for Cancer Control (NRDPCC), Ministry of Health and Welfare, Republic of Korea, and Ethicon Endo-Surgery, a Johnson & Johnson Company. Some authors reported receiving grants or personal fees from various sources, including NRDPCC and Ethicon Endo-Surgery.

Source: Son SY et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2749

Key clinical point: Laparoscopic distal gastrectomy was surgically and oncologically noninferior to open distal gastrectomy in patients with locally advanced gastric cancer throughout the 5-year follow-up period.

Major finding: Patients who underwent laparoscopic vs open distal gastrectomy had a significantly lower late complication rate (6.5% vs 11.0%; P  =  .01), but similar 5-year overall survival (88.9% vs 88.7%; P  =  .30) and relapse-free survival (79.5% vs 81.1%; P  =  .658) rates.

Study details: This study reports the 5-year follow-up results of the KLASS-02 trial that included 974 patients with locally advanced gastric cancer who underwent R0 resection by laparoscopic (n = 492) or open (n = 482) distal gastrectomy.

Disclosures: This study was sponsored by the National R&D Program for Cancer Control (NRDPCC), Ministry of Health and Welfare, Republic of Korea, and Ethicon Endo-Surgery, a Johnson & Johnson Company. Some authors reported receiving grants or personal fees from various sources, including NRDPCC and Ethicon Endo-Surgery.

Source: Son SY et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2749

Key clinical point: Laparoscopic distal gastrectomy was surgically and oncologically noninferior to open distal gastrectomy in patients with locally advanced gastric cancer throughout the 5-year follow-up period.

Major finding: Patients who underwent laparoscopic vs open distal gastrectomy had a significantly lower late complication rate (6.5% vs 11.0%; P  =  .01), but similar 5-year overall survival (88.9% vs 88.7%; P  =  .30) and relapse-free survival (79.5% vs 81.1%; P  =  .658) rates.

Study details: This study reports the 5-year follow-up results of the KLASS-02 trial that included 974 patients with locally advanced gastric cancer who underwent R0 resection by laparoscopic (n = 492) or open (n = 482) distal gastrectomy.

Disclosures: This study was sponsored by the National R&D Program for Cancer Control (NRDPCC), Ministry of Health and Welfare, Republic of Korea, and Ethicon Endo-Surgery, a Johnson & Johnson Company. Some authors reported receiving grants or personal fees from various sources, including NRDPCC and Ethicon Endo-Surgery.

Source: Son SY et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial. JAMA Surg. 2022 (Jul 20). Doi: 10.1001/jamasurg.2022.2749